News
The latest AHA Today headline news stories.
The AHA today launched a virtual postcard series of #ForeverGrateful messages expressing appreciation for the efforts of health care workers in their communities.
About four in 10 eligible U.S. adults aged 65 or older received a booster or additional primary dose of COVID-19 vaccine between Aug. 13 and Nov. 19, with lowest coverage among American Indian or Alaska Native (30%), Hispanic or Latino (34%), and Native Hawaiian or other Pacific Islander persons (…
The Medicare Payment Advisory Commission this week discussed several draft recommendations for Congress, which the panel would vote on in January.
As urged by the AHA, the Senate last night voted 59-35 to pass legislation that would stop Medicare cuts to hospitals, physicians and other providers from going into effect early next year.
This week Congress passed legislation to stop a number of harmful cuts to Medicare payments for hospitals, physicians and other providers that were scheduled to kick in at the beginning of next year.
The AHA and American Medical Association today sued the federal government over the misguided implementation of the federal surprise billing law.
A federal district court in Louisiana late yesterday issued a preliminary injunction placing a temporary hold on enforcement of the Centers for Medicare & Medicaid Services vaccine mandate for health care facilities in all states, except the 10 already covered by the Missouri district court’s…
The California and San Francisco Departments of Public Health have confirmed the first case of the omicron variant in the United States in an individual in California who was fully vaccinated against COVID-19 and returned Nov. 22 from South Africa, the Centers for Disease Control and Prevention…
Teleflex has recalled a percutaneous thrombolytic device kit due to reports that a component could detach from the device and embolize.
The Food and Drug Administration’s Antimicrobial Drugs Advisory Committee late yesterday voted to recommend an emergency use authorization for Merck’s investigational oral antiviral COVID-19 medicine. The drug, molnupiravir, is meant for the treatment of mild-to-moderate COVID-19 in at-risk adults.